Tight ligand-receptor binding, paradoxically, is a major root of drug resistance in cancer chemotherapy. To address this problem, instead of using conventional inhibitors or ligands, this paper focuses on the development of a novel process-enzyme-instructed self-assembly (EISA)-to kill cancer cells selectively. Here it is demonstrated that EISA as an intracellular process to generate nanofibrils of short peptides for selectively inhibiting cancer cell proliferation, including drug resistant ones. As the process that turns the non-self-assembling precursors into the self-assembling peptides upon the catalysis of carboxylesterases ( 
Introduction
This article reports that carboxylesterases (CES) convert non-self-assembling precursors into self-assembling peptides that form intracellular nanofibrils to selectively inhibit cancer cells. Due to genomic instability, cancers usually evolve to drug resistant tumors and results in high mortality. [1] Targeting a specific protein or nucleic acid or a critical enzyme, molecular therapy has made significant progresses in the last two decades. However, largely due to the almost inevitable relapse in the patients with advanced cancers to develop drug resistance, chemotherapy, and molecular therapy are still unable to meet all the need of cancer therapy, particularly in cancers that are still lack of immunotherapy. For example, due to the low level expression of cancer specific antigens (e.g., PD-L1) [2] or the presence of other immunosuppressive mechanism, [3] considerable types of cancers (e.g., glioma and ovarian adenocarcinoma) respond poorly to cancer immunotherapy. [4] Thus, there is urgent need of a new approach for addressing such a gap in cancer therapy. [5] Being evolved from supramolecular chemistry, [6] especially supramolecular gels, [7] and hydrogels, [7, 8] enzyme-instructed self-assembly (EISA), that is, the integration of enzymatic catalysis and molecular self-assembly, has emerging as a multiple step process for selectively inducing cancer cell death. [9] We have been working on the application of EISA inside cells, [9a,10] as well as in pericellular space, [9b] for inducing cancer cell death selectively. [11] Our works on nanofibrils of small peptides also reveal that the promiscuous interactions between the nanofibrils and cytoskeleton proteins (e.g., actins) lead to selective inhibition of cancer in cell assay [12] and in animal model. [9b] Wells and co-workers reported the self-assembly of small mole cules into nanofibrils that can cause cell death via multiple mechanisms. [13] Recently, Maruyama and co-workers, [14] Pires and co-workers, [8c] and Yang and co-workers, [8g,15] also reported inhibition of cancer cells by supramolecular nanofibrils generated by EISA. Gao and co-workers reported the use of phosphatase-based EISA for cancer theranostics in a mice model. [16] Most recently, we demonstrated that intracellular nanofibrils formed by EISA are able to enhance the activity of cisplatin against platinum resistant ovarian cancer cells. [17] Despite these exciting and promising progresses of EISA, the need of cisplatin remains a limitation because of the poor selectivity cisplatin itself. In addition, the relevant modality of cell death caused by the intracellular nanofibrils has yet to be determined.
The exceptional selectivity [18] and fundamentally new mechanisms [9b,12] of EISA, as a process, against cancer cells encouraged us to further develop EISA for inhibiting cancer cell proliferation. Encouraged by the development of prodrugs based on CES, [19] we explore CES-based EISA for inducing cancer cell death. CES, a kind of esterase found in human organ and tissues, serves an important role in hydrolyzing esters. The installation of ester bond in the prodrugs can help improve the lipophilicity, selectivity, solubility and other properties of the parent drugs. [20] Among all the marketed prodrugs, about half of them are esters that require the activation by esterases. For example, CPT-11 is an anticancer prodrug with better aqueous solubility, which can be converted into its active metabolite SN-38 by CES with enhanced cytotoxicity. [19b] Despite it consists of the step of enzymatic transformation, EISA differs from the prodrug approach [19c,21] because only the supramolecular assemblies, not the monomeric, unassembled products of the enzymatic conversion, are inhibitory to cancer cells. [9b,c] We decide to examine the correlation of the activities of CES and the inhibition efficacy of EISA in a range of cancer cells. Specifically, we explore EISA of a pair of enantiomeric dipeptide and taurine conjugates (l-and d-DPT) installed with ester bond between the dipeptides [12] and taurine [22] for inhibiting drug resistant cancer cells. We develop the non-self-assembling precursors (i.e., the conjugates, l-or d-DPT) that turn into the self-assembling molecules (i.e., the dipeptides, l-or d-DP) upon intracellular hydrolysis catalyzed by CES. We find that the precursors selectively inhibit cancer cells (e.g., HCC1937, MCF-7, SKOV3, A2780, A2780cis, HeLa, MES-SA, and Saos-2) without inducing death of normal cells (e.g., stromal cells HS-5). The inhibitory activities of the precursors correlate with the activities of the CES of the cells. Our results confirm that the overexpression of CES in cancer cells is responsible for selective inhibition of the cancer cells by the EISA of the dipeptides. Our study also reveals that the formation of the intracellular nanofibrils disrupts the dynamics of actin filament to cause either apoptosis or necroptosis of the cancer cells [17] (Figure 1 ; Figures S1 and S2, Supporting Information). Moreover, d-DPT always exhibit higher inhibitory activities than the l-DPT, agreeing with the proteolytic stability of d-DPT and d-DP. By establishing intracellular EISA for selectively inhibiting cancer cell proliferation, this work illustrates a new approach that relies on enzymatic reaction (not on enzyme inhibition) to amplify the difference between cancer and normal cells for selectively killing the cancer cells.
Results and Discussion
We design and synthesize an enantiomeric pair of N-terminal capped diphenylalanine that conjugates with taurine as the precursors (i.e., l-or d-DPT). After the hydrolytically removal of the taurine moiety by an esterase, the corresponding products, dipeptides (i.e., l-or d-DP), self-assemble in water to form nanofibrils. Both the precursors and the dipeptides can be easily made in large quantities by a facile synthetic route that combines liquid phase synthesis and solid-phase peptide synthesis (SPPS). In this design, naphthyl capped diphenylalanine (NapFF) [23] serves as the self-assembly motif to provide aromatic-aromatic interactions for enhancing intermolecular hydrogen bonds between the dipeptides in water. With the installed ester bond linked taurine on the precursors, CES can convert the non-self-assembling precursors (l-or d-DPT) to self-assembling dipeptide derivatives (l-or d-DP), which self-assemble to form nanofibrils. [17] We choose to test an enantiomeric pair because the biostability of the dipeptides in cellular environment is an important aspect of pharmacokinetics. Particularly, the enantiomer composed by d-amino acids (d-DPT) can resist the degradation of endogenous proteases, thus warrants the long term function of the self-assembled peptide nanofibrils. Beside the difference in proteolytic stability of each peptide, self-assembly kinetics of the peptides could also be different, which cause the difference in efficacy. However, since l-DPT and d-DPT exhibit similar hydrolysis rates ( Figure S3 , Supporting Information) upon the addition of esterase (0.1 U mL −1 ), proteolytic stability likely would be the major factor. After the synthesis of l-DPT and d-DPT, we purify the crude compounds by high performance liquid chromatography (HPLC) and characterize the purified compounds by (3 of 9) 1601400 NMR and LC-MS. [17] It is relatively easy to produce gram quantity of these derivatized dipeptides.
Inhibitory Activities of the Precursors on Multiple Cell Lines
After obtaining the precursors, we test the cytotoxicity of l-DPT (or d-DPT) on multiple cell lines including cancer cells and normal cells (Figure 2 ) and summarize the IC 50 values of the third day (i.e., 72 h) in µg mL −1 (Figure 3A,B) . We test the precursors on two breast cancer cell lines-HCC1937, a line of triple negative breast cancer cells (TNBC), and MCF-7, a common breast cancer cell line. As summarized in Figure 2 and Figure 3A This assumption is confirmed by in vivo toxicity examination (vide infra) in mice. Being tested on two glioblastoma cell lines (U87MG and T98G), l-DPT shows little cytotoxicity toward these two cancer cell lines at or below concentration of 146 µg mL −1 . The cell viabilities of U87MG and T98G cells, after being treated by 365 µg mL −1 of l-DPT, are about 70% and 60%, respectively. d-DPT exhibits higher inhibitory activity toward to these two cell lines, with the IC 50 values of 126 and 145 µg mL −1 at 72 h incubation of U87MG and T98G, respectively. As a control experiment, we test the cytotoxicity of the precursors on two normal cell lines-HS-5, a stromal cell derived from normal bone marrow, [24] and PC12, a model neuron cell line from mice. Both l-DPT and d-DPT show little cytotoxicity on these two cell lines. The IC 50 values of l-DPT on HS-5 and PC-12 are 99 and 106 µg mL −1 , respectively, which are higher than the IC 50 values of l-DPT on most of the cancer cell lines we tested. The IC 50 values of d-DPT on HS-5 and PC-12 are 50 and 62 µg mL −1 , respectively, which are also two to three times higher than the IC 50 values of d-DPT against most of the cancer cells tested.
To assess the selectivity of l-DPT and d-DPT toward cancer cells, we compare their activities on drug resistant ovarian cancer cells (A2780cis and SKOV3) and the stromal cells (HS-5) at about the IC 90 of the inhibitors against the cancer cells. As shown in Figure 4A , l-DPT, at 73 µg mL −1 , shows high cytotoxicity on both A2780cis and SKOV3 cells (ovarian cancer cells) and inhibits almost 100% of the cancer cells on the third day. At the same concentration, l-DPT hardly inhibits the HS-5 cell (and the cell viability is about 80% on the third day). d-DPT also shows potent cytotoxicity toward ovarian cancer cells, especially to SKOV3 cells. d-DPT, at 37 µg mL −1 , inhibits more than 90% of SKOV3 cells and about 55% of A2780cis cells on the third day. Treated by d-DPT at 37 µg mL −1 , HS-5 cells exhibit about 80% viability at day 3. These results confirm that the two precursors are able to selectively inhibit ovarian cancer cells at their IC 90 with little inhibition to HS-5 cells. As another positive control, we test the cytotoxicity of cisplatin on those two ovarian cancer cell lines. Cisplatin, which is known as a powerful anticancer drug can inhibit 90% of SKOV3 cells and about 98% of A2780cis cells on the third day at concentration of 37 µg mL −1 . However, cisplatin (37 µg mL −1 ) kills almost 100% of HS-5 on the third day. This result indicates the limitation of cisplatin, agreeing with that cisplatin has little selectivity and may cause high systematic toxicity to normal cells. Interestingly, l-DPT, at 37 µg mL −1 , is innocuous to those two ovarian cancer cells, as well as to normal cells. This result implies that the proteolytic instability of l-DPT in cellular environment likely contribute to its low cytotoxicity toward SKOV3 and A2780cis.
Cytotoxicity of EISA on Cocultured Cells
To further verify that intracellular EISA selectively inhibits cancer cells, we coculture the stromal cells (HS-5) cells together with the drug resistant ovarian cancer cells (SKOV3 or A2780cis cells). We seed 5 × 10 3 of SKOV3 cells (or A2780cis) and 5 × 10 3 HS-5 cells per well together and coculture them in Dulbecco's Modified Eagle Medium (DMEM). Based on the results in Figure 4A , we choose to use the concentrations of l-DPT and d-DPT at 73 and 37 µg mL −1 , respectively. As shown in Figure 4B , precursor l-DPT at 73 µg mL −1 shows cytotoxicity to the cocultured HS-5 and SKOV3 cells, which causes about 60% of cell death on the third day. The efficacy of l-DPT (73 µg mL −1 ) on cocultured HS-5 and A2780cis cells is comparable to its efficacy on cocultured HS-5 and SKOV3 cells as it inhibits about 57% of cells on the third day. As shown in Figure 4A , cancer cells (SKOV3, A2780cis) were inhibited almost by 100% on the third day after the treatment of the same concentrations of l-DPT (73 µg mL (5 of 9) 1601400 (37 µg mL −1 ) are 79% and 80%, respectively. While on the third day, the cell viabilities drop to 44% and 57%, respectively. In addition, after being treated by the same concentration of d-DPT (37 µg mL 
Quantification of Esterase Activities in Multiple Cell Lines
To evaluate the contribution of the expression of CES for the observed selectivity against the cancer cells, we quantify the esterase activities in those cell lines ( Figure 5 ). Figure S5 (Supporting Information), except for HepG2, U87MG, and T98G, the precursor shows high cytotoxicity (i.e., low IC 50 values) to the cells that exhibit high esterase activities. Although normal cells also exhibit esterase activity, which is two to four times lower than the esterase activities in cancer cells. The much lower esterase activity in normal cells results in slow conversion of the precursors inside the cells so that the precursors show lower toxicity to normal cells than to the cancer cells. We treat HeLa cell, HS-5 cells, and HOSE-636 cell (human ovarian surface epithelium) with d-DPT at 37 µg mL −1 or l-DPT at 73 µg mL −1 for 12 h, and then we stain the cell with Congo red (a dye to indicate the formation of nanofibers) and Hoechst (nuclei). As shown in Figures S6-S8 (Supporting Information), HeLa cells treated with the precursors show bright red fluorescence, which indicates the formation of nanofibers inside cells. However, both HS-5 and HOSE-636 show little red fluorescence. These results confirm that there are more nanofibers formed inside cancer cells than in normal cells. We also summarize the substrate fluorescence versus total cell number ( Figure S9 , Supporting Information). The general trend is similar to the result obtained by normalizing to the total protein amount, and that normal cell (HS-5) still has the lowest amount of esterase.
Determination of the Modality of Cell Death
In order to determine the modality of cell death [25] caused by intracellular EISA, we use the pan caspase inhibitor zVADfmk, [26] which is an antiapoptotic agent that can inhibit caspase activities, to treat the cancer cells together with l-DPT and d-DPT to test the roles of caspases in the cell death process. As shown in Figure 6A ,B, there is hardly obvious difference with and without the addition of zVAD-fmk (45 × 10 −6 m) into the l-DPT treated SKOV3 or A2780cis cells. This result indicates that EISA of l-DPT causes death of SKOV3 or A2780cis via caspase-independent mechanism. [27] Contrasting to the case of l-DPT, the addition of zVAD-fmk (45 × 10 −6 m) significantly increases the viability of the SKOV3 cell treated the d-DPT (37 µg mL −1 ) from 10% to 77% ( Figure 6C ), indicating apoptotic dependence at that concentration. This observation suggests the mechanism of cell death depends on the concentrations of l-DPT (or d-DPT), which agrees with the notion of EISA. However, zVAD-fmk hardly increases the cell viability when 73 µg mL −1 of d-DPT treats the SKOV3 cells. While d-DPT at 37 µg mL −1 largely leads to apoptosis, d-DPT at 73 µg mL −1 apparently causes caspase independent cell death of SKOV3. These results suggest that the modality of cell death of SKOV3 depends on the amount of intracellular nanofibrils of (7 of 9) 1601400 only insignificantly increase (10%) cell viability ( Figure 6D ), suggesting that apoptosis unlikely is the major cause of the death of A2780cis cell. Nec-1 (Necrostatin-1), [28] which is an inhibitor of necroptosis, a mechanism of programmed cell death different from apoptosis, is also used to treat the cancer cells. As shown in Figure 7A , SKOV3 cells with the treatment of 50 × 10 −6 m of Nec-1 together with l-DPT at or above 73 µg mL −1 show slightly higher cell viability (about 15%) comparing with the cells treated by l-DPT alone. The difference between the cell viabilities of A2780cis cells treated with l-DPT alone and the combination of Nec-1 and l-DPT is insignificant either (10%) ( Figure 7B ). Similar trend is shown in the case of d-DPT that the difference with or without the addition of Nec-1 (50 × 10 −6 m) into d-DPT treated SKOV3 cells or A2780cis cells is about 20% or 13%, respectively ( Figure 7C,D) . The significant increase of the cell viability after the addition of Nec-1 indicates that necroptosis contributes to cell death but is unlikely the major cause of the death of SKOV3 cells and A2780cis cells as SKOV3 and A2780cis cell viabilities are unable to return to 100%. This observation indicates that cell death likely is resulted from multiple mechanisms.
In Vivo Toxicity of the Precursors of EISA
To further validate that the precursors are nontoxic to normal tissues, we test the in vivo toxicity of the precursors in mice. As shown in Figure S10A (Supporting Information), the body weights of mice treated with phosphate buffered saline (PBS) or l-DPT at concentrations of 5, 10, and 20 mg kg −1 are statistically same, indicating that l-DPT hardly cause obvious adverse effects on the growth of mice. Figure S10B ,C (Supporting Information) shows the calculated thymus and spleen indexes, which reflex the immune response of mice to the precursor l-DPT. The difference between the control group (PBS buffer) and l-DPT group is insignificant, indicating that the intravenous injection of the precursors unlikely causes immune response of mice. Figure S10D (Supporting Information) shows the hematology results, including the values of white blood cells, red blood cells, hematocrit, hemoglobin, mean corpuscular volume, mean corpuscular hemoglobin concentration, mean corpuscular hemoglobin, and platelet. There are no significant differences observed between the control group and l-DPT group on all the standard markers of hematology detected in the study. This result confirms that l-DPT hardly induces inflammatory responses in major organs even at a dosage of 20 mg kg −1 . Furthermore, we also examine the blood biochemistry indicators such as alanine transaminase, aspartate transaminase, alkaline phosphatase, albumin, total protein, total bilirubin, creatinine, urea, and blood urea nitrogen to analyze the influence of l-DPT on the liver and kidney functions of mice ( Figure S10E , Supporting Information). These indicators confirm that l-DPT is innocuous on the liver and kidney functions of mice. Same in vivo toxicity study are carried out with d-DPT at the same dosages, which show similar results ( Figure S11 
Conclusion
In conclusion, by establishing cytosolic enzymes-instructed self-assembly as an anticancer process, this work illustrates a fundamentally new approach to amplify the enzymatic difference between cancer and normal cells for overcoming cancer drug resistance. Although we demonstrated that EISA of dipeptides can selectively inhibit a range of cancer cells, other molecules that are prone to self-assembly or aggregate in water [29] may serve as the candidates for developing EISA. Figure S13 , Supporting Information). This result suggests that the rate of EISA controls cell fate. Besides, we also discover that the precursors (l-DPT and d-DPT) show higher inhibitions on SKOV3 cells (platinum-resistant cell line) than on A2780 cells (platinum sensitive cell line), which reveals that the precursors inhibit drug resistant cancer cells with high activity. Our study reveals that U87MG, T98G, and MES-SA/ Dx5 are insensitive to intracellular EISA, which warrants to explore different approaches, such as pericellular EISA of small peptides [9b] or combination therapy, [17] for selectively inhibiting those cancer cells. Moreover, considering the fundament difference between EISA and the conventional prodrug approach, we envision that EISA ultimately may lead to a new therapy, which uses enzyme controlled dynamics of self-assembly of other molecules [30] or entities, [31] for detecting and treating cancers. Although the esterase activity in extracellular space may decrease the in vivo efficacy of the precursors by prematurely hydrolyzing the precursors, it is possible to use a cell-impermeable esterase inhibitor together with the precursors for selectively targeting cancer cells in vivo, which is part of on-going research.
Experimental Section
Reagents: The reagents used such as N,N-diisopropylethylamine, O-benzotriazole-N,N,N′,N′-tetramethyluronium-hexafluorophosphate, N,N′-diisopropylcarbodiimide, N-hydroxysuccinimide, and taurine were purchased from ACROS Organics USA. All other amino acid derivatives were purchased from GL Biochem (Shanghai) Ltd. The synthesis of l-DPT and d-DPT have been reported previously [17] so it is only described briefly here. The liquid phase synthesis and SPPS were combined together for synthesizing l-DPT and d-DPT and the crude compounds were purified by HPLC with an overall yield at about 60%.
Cell Culture: All cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA). Cells were seeded in the density of 10 4 cells per well in 96-well plates. U87MG, T98G, HepG2, HeLa and MCF-7 cells were maintained in MEM medium supplemented with 10% fetal bovine serum (FBS), 100 U mL −1 penicillin and 100 µg mL −1 streptomycin. A375 and HS-5 cells were maintained in DMEM supplemented with 10% FBS, 100 U mL −1 penicillin, and 100 µg mL −1 streptomycin. MES-SA, MES-SA/Dx5, and SKOV3 cells were maintained in McCoy's 5A medium modified supplemented with 10% FBS, 100 U mL −1 penicillin, and 100 µg mL −1 streptomycin. A2780, A2780cis and HCC1937 cells were maintained in PRMI-1640 medium supplemented with 10% FBS, 100 U mL −1 penicillin, and 100 µg mL −1 streptomycin. Saos-2 cells were maintained in McCoy's 5A medium modified supplemented with 15% FBS, 100 U mL −1 penicillin, and 100 µg mL −1 streptomycin. PC12 cells were maintained in F-12K supplemented with 10% horse serum, 5% FBS. All cells were grown at 37 °C, 5% CO 2 .
MTT Assay: According to previously reported procedure, [32] cell viability was examined by MTT assay.
Measurement of Esterase Activity: 80 µL of 6-carboxyfluorescein diacetate (25 × 10 −6 m in PBS buffer) was used to stain cells in each well. After incubation at 37 °C in dark for 30 min, the fluorescence of each well was determined by microplate reader equipped with 485 nm excitation and 535 nm emission filter. The esterase activity values were calculated by using the fluorescence units got from the plate reader divided by cell protein weight (pg) per well.
In Vivo Toxicity: Mice were randomly divided into seven groups: PBS buffer, l-DPT at 5, 10, and 20 mg kg −1 , respectively, d-DPT at 5, 10, and 20 mg kg −1 , respectively. Each group includes 12 mice and 4 mice per time point (day 1, day 4, and day 7). l-DPT and d-DPT were dissolved in 100 µL PBS buffer to achieve the above mentioned concentrations. PBS buffer or the diluted samples was administrated via the tail vein for one administration. Mice body weights were monitored every day for 7 d since the administration. Thymus and spleen were harvested on day 1, day 4, and day 7 to study the immune response of mice. Hematological and biochemical analysis were performed on day 1, day 4, and day 7 by automatic blood analyzer using whole blood samples collected from eyes at the designated time points. H&E assays were performed using the heart, liver, kidney, lung, and spleen harvested on day 7.
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